title: Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique.
abstract: The effectiveness of anidulafungin versus liposomal amphotericin B (LAmB) for treating experimental Candida parapsilosis catheter-related infection by an antifungal-lock technique was assessed.
  
  
  
  Two clinical strains of C. parapsilosis (CP12 and CP54) were studied. In vitro studies were used to determine the biofilm MICs (MBIC50 and MBIC90) by XTT reduction assay and LIVE/DEAD biofilm viability for anidulafungin and LAmB on 96-well microtitre polystyrene plates and silicone discs. An intravenous catheter was implanted in New Zealand white rabbits. Infection was induced by locking the catheter for 48 h with the inoculum. The 48 h antifungal-lock treatment groups included control, 3.3 mg/mL anidulafungin and 5.5 mg/mL LAmB.
  
  
  
  Anidulafungin showed better in vitro activity than LAmB against C. parapsilosis growing in biofilm on silicone discs. MBIC90 of LAmB: CP12, >1024 mg/L; CP54, >1024 mg/L. MBIC90 of anidulafungin: CP12, 1 mg/L; CP54, 1 mg/L (P ≤ 0.05). Moreover, only anidulafungin (1 mg/L) showed >90% non-viable cells in the LIVE/DEAD biofilm viability assay on silicone discs. No differences were observed between the in vitro susceptibility of anidulafungin or LAmB when 96-well plates were used. Anidulafungin achieved significant reductions relative to LAmB in log10 cfu recovered from the catheter tips for both strains (P ≤ 0.05). Only anidulafungin achieved negative catheter tip cultures (CP12 63%, CP54 73%, P ≤ 0.05).
  
  
  
  Silicone discs may be a more reliable substrate for the study of in vitro biofilm susceptibility of C. parapsilosis. Anidulafungin-lock therapy showed the highest activity for experimental catheter-related infection with C. parapsilosis.
authors.affiliation: Infectious Diseases Research Laboratory, Vall d'Hebron Research Institute, VHIR, Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Jana
authors.initials: J
authors.lastname: Basas
authors.affiliation: Infectious Diseases Research Laboratory, Vall d'Hebron Research Institute, VHIR, Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Alba
authors.initials: A
authors.lastname: Morer
authors.affiliation: Infectious Diseases Research Laboratory, Vall d'Hebron Research Institute, VHIR, Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Ratia
authors.affiliation: Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Martín
authors.affiliation: Infectious Disease Division, Laboratory of Microbial Biofilms, Clínica Universidad de Navarra, Navarra, Spain.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Del Pozo
authors.affiliation: Infectious Diseases Research Laboratory, Vall d'Hebron Research Institute, VHIR, Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: Gomis
authors.affiliation: Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain.
authors.forename: Estrella
authors.initials: E
authors.lastname: Rojo-Molinero
authors.affiliation: Institute for Bioengineering of Catalonia (IBEC), Bacterial Infections and Antimicrobial Therapies, Barcelona, Spain.
authors.forename: Eduard
authors.initials: E
authors.lastname: Torrents
authors.affiliation: Infectious Diseases Research Laboratory, Vall d'Hebron Research Institute, VHIR, Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Benito
authors.initials: B
authors.lastname: Almirante
authors.affiliation: Infectious Diseases Research Laboratory, Vall d'Hebron Research Institute, VHIR, Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain joan.gavalda@vhir.org.
authors.forename: Joan
authors.initials: J
authors.lastname: Gavaldà
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D055499:Catheter-Related Infections / Q000188:drug therapy* / Q000382:microbiology*; D002408:Catheters, Indwelling / Q000382:microbiology; D054714:Echinocandins / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D012828:Silicones
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D012828:Silicones; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077612:Anidulafungin